New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
12:15 EDTAZN, MYLAstraZeneca wins appeal to block generic Seroquel XR from Mylan, others
After a New Jersey district court ruled last March that AstraZeneca's (AZN) formulation patent protecting Seroquel XR extended release tablets was valid, the U.S. Court of Appeals for the Federal Circuit affirmed the lower court's ruling today. The lower court had also ruled that Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals and Mylan Pharmaceuticals (MYL) have infringed the Seroquel XR formulation patent, which expires in 2017. Reference Link
News For AZN;MYL From The Last 14 Days
Check below for free stories on AZN;MYL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 25, 2014
06:11 EDTMYLMylan downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
July 24, 2014
14:35 EDTMYLObama to call for elimination of tax inversion deals, NY Times says
President Obama will call on Congress today to eliminate the tax inversion loophole, according to The New York Times. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott’s (ABT), Medtronic's acquisition of Covidien (COV)and Valeant's (VRX) proposed takeover of Alletgan (AGN)Reference Link
July 23, 2014
10:02 EDTMYLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMYLDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
07:09 EDTMYLMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
06:45 EDTMYLLawmakers divided on inversion deals, NY Times says
Subscribe for More Information
July 22, 2014
16:08 EDTMYLMylan initiated with a Buy at Deutsche Bank
Target $67.
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 18, 2014
16:47 EDTMYLMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTMYLKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 17, 2014
11:07 EDTMYLAcorda sues Mylan over plans to duplicate Ampyra MS drug, Bloomberg says
07:18 EDTMYLMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
July 16, 2014
10:36 EDTMYL, AZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:03 EDTMYLSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
08:16 EDTMYLLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZN, MYLTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 15, 2014
14:40 EDTMYLEarnings Preview: Abbott targets continued gains in emerging markets
Subscribe for More Information
11:17 EDTMYLStocks with call strike movement; KORS MYL
Subscribe for More Information
06:15 EDTMYLAbbott unit sale to Mylan 'a wash,' says Citigroup
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use